pharmaphorum May 17, 2024
Artificial intelligence company Brainomix has claimed FDA approval for e-Lung, which assists in the diagnosis and assessment of patients with interstitial lung diseases (ILDs) from medical images.
Brainomix has built its business on the back of its suite of tools and algorithms for interpreting brain scans and guiding treatment and transfer decisions for stroke patients, but it has been working to expand into new areas.
The FDA approval of e-Lung is the first for the University of Oxford spin-out in lung disease, its next major area of focus along with cancer, and also marks a step up in its presence in the US.
ILDs are a broad category of over 200 lung diseases that can cause scarring (fibrosis) to the...
Today's Sponsors
Today's Sponsor